clinical trial · NCT05019950
Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers
NImmune Biopharma·phase1·completed·n = 56
Normal Healthy VolunteersNIM-1324Placebo
brief summary
This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The primary objective of this study is to assess the safety and tolerability of single and 7-day repeat oral doses NIM-1324 in healthy adult volunteers.
started
Oct 28, 2021
primary completion
Apr 28, 2022
completion
Apr 28, 2022
last updated
Jun 8, 2023
official title
A Randomized, Placebo-Controlled, Double-Blind, Single-Center Study to Evaluate Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol